Actively Recruiting
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Led by Peking University First Hospital · Updated on 2024-05-31
100
Participants Needed
3
Research Sites
346 weeks
Total Duration
On this page
Sponsors
P
Peking University First Hospital
Lead Sponsor
P
Peking University Third Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the economy. Current treatment guidelines only provide partial control, leading to varying remission times and recurrence rates. This study aims to use molecular subtyping and immunohistochemistry to guide treatment selection for CTCL patients, aiming to prolong clinical benefit, improve treatment safety, and reduce economic burden.
CONDITIONS
Official Title
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Diagnosis of cutaneous T-cell lymphoma (CTCL) not responding well to early or advanced stage targeted skin therapies
- Age between 18 and 75 years
- Expected survival time of more than 3 months
You will not qualify if you...
- Received anti-tumor treatments other than skin-targeted therapy within 1 month before enrollment
- Having two or more types of primary cutaneous T-cell lymphoma simultaneously
- Having other malignant tumors currently receiving anti-tumor therapy
- Presence of active diseases increasing therapy risks or impairing treatment ability, including epilepsy, autoimmune diseases, liver failure, or kidney insufficiency with creatinine clearance below 50 ml/min
- Uncontrolled medical conditions such as active infections, significant heart or lung diseases, healing wounds, or psychiatric/social issues affecting study compliance
- Pregnant or lactating women, or planning pregnancy within 2 years
- Participation in other interventional drug clinical trials
- Any situation or condition deemed unsuitable by the investigator for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
2
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
3
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Actively Recruiting
Research Team
Y
Yang Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here